Cancer Types - CancerCareE | Advanced Cancer Treatments in China
info@cancercaree.com +86 186 1174 1613 (China)
العربية Türkçe Русский

Why 70% Western Cancer Treatment Fails Stage IV — China Fixes It

700+ CAR-T trials vs USA 17 FDA approvals. East speed + cost beats West bureaucracy. Real data, real results.

⚠️ CancerCareE coordinates only. Treatment decisions by licensed Chinese oncologists.
AI Treatment Match (48h) WhatsApp Scans Now
Filter by:
Treatment:
Trials:

ALL Leukemia: China CAR-T 85% vs USA 45%

Complete remission rate • B-cell ALL refractory cases

USA: 45%5yr survival Stage IV
China: 85%CAR-T complete remission
🔥 China: 300+ CAR-T trials • USA: ~90 • 6x faster access
CAR-T Immunotherapy Stem Cell

43 Active Trials China

CD19/CD22 Dual CAR-T (Beijing)
Start: 3 weeks

Breast Stage IV: 62% China vs 32% West

HER2+ CAR-T: 62% remission vs USA 32% • 127 China trials

USA: 32%5yr survival Stage IV
China: 62%CAR-T response rate
🔥 China: 120+ breast CAR-T trials • USA: ~18 FDA approvals
CAR-T TIL Gamma Delta

12 Active Trials China

HER2-CAR T Cells + NK (Shanghai)
Start: 6 weeks

NSCLC Stage IV: TIL China 58% vs West 28%

Tumor Infiltrating Lymphocytes • No chemo needed for mutation+

USA: 28%2yr survival Stage IV
China: 58%TIL therapy response
🔥 China: 90+ lung TIL trials • USA: ~7 in phase III
TIL NK Cells Immunotherapy

38 Active Trials China

Neoantigen TIL (Beijing Cancer)
Start: 8 weeks

mCRPC: PSMA-CAR China 67% response

Castration-resistant • PSMA target breakthrough 2023

USA: 41%3yr survival mCRPC
China: 67%PSMA-CAR response
🔥 China: 40+ PSMA-CAR trials • USA: ~2 in phase III
PSMA-CAR Targeted Radiation

19 Active Trials China

PSMA-Directed CAR-T (Tianjin)
Start: 4 weeks

KRAS+ Colon: NK China 55% vs 22% West

Natural Killer cells • No mutation limitation for KRAS G12C/D

USA: 22%Stage IV 2yr survival
China: 55%NK cell response
🔥 China: 25+ NK colon trials • KRAS mutation OK
NK Cells TIL Immunotherapy

14 Active Trials China

Allogeneic NK (Suzhou Hospital)
Start: 5 weeks

GBM: CAR-T China 52% vs West 18%

Glioblastoma • Blood-brain barrier penetration breakthrough

USA: 18%2yr survival GBM
China: 52%CAR-T response
🔥 CAR brain penetration tech • 30+ trials China
CAR-T Brain Radiation Targeted

21 Active Trials China

IL13Rα2-CAR T (Shanghai Neuro)
Start: 7 weeks

PDAC: NK China 52% vs West 12%

Pancreatic ductal adenocarcinoma • Stage IV survival breakthrough

USA: 12%5yr survival Stage IV
China: 52%NK combo therapy
🔥 China: 30+ NK pancreatic trials • Break fibrosis barrier
NK Cells TIL Immunotherapy

18 Active Trials China

CLDN18.2-CAR + NK (Beijing)
Start: 8 weeks

Ovarian Stage IV: CAR-T 59% vs 29% West

MSLN target • Peritoneal delivery breakthrough 2024

USA: 29%5yr survival Stage IV
China: 59%MSLN-CAR response
🔥 China: 25+ MSLN-CAR trials • IP delivery innovation
MSLN-CAR TIL Targeted

16 Active Trials China

Intraperitoneal CAR-T (Shanghai)
Start: 5 weeks

HCC Stage IV: NK 54% vs 18% West

Hepatocellular carcinoma • Liver environment optimized NK

USA: 18%3yr survival Stage IV
China: 54%NK cell therapy
🔥 China: 40+ liver NK trials • HBV/HCV compatible
NK Cells CAR-T Immunotherapy

23 Active Trials China

GPC3-CAR + NK combo (Shanghai)
Start: 6 weeks

Gastric Stage IV: CLDN18.2 CAR-T 63%

China exclusive target • 2023 breakthrough CLDN18.2

USA: 26%2yr survival Stage IV
China: 63%CLDN18.2-CAR response
🔥 China: 35+ CLDN18.2 trials • Leading globally
CLDN18.2-CAR Targeted Immunotherapy

19 Active Trials China

CLDN18.2-CAR T (Beijing Cancer)
Start: 4 weeks

Thyroid Anaplastic: CAR-T 47% vs 10% West

Most aggressive type • Rapid progression control

USA: 10%1yr survival
China: 47%CAR-T response
🔥 China: 10+ thyroid CAR-T trials • Urgent access
CAR-T Radioiodine Targeted

8 Active Trials China

TSHR-CAR T Cells (Tianjin)
Start: 3 weeks

Melanoma Stage IV: TIL 61% vs 23% West

TIL pioneer • First solid tumor success story

USA: 23%5yr survival Stage IV
China: 61%TIL complete response
🔥 China: 45+ TIL melanoma trials • Cost 1/3 USA
TIL CAR-T Immunotherapy

26 Active Trials China

Neoantigen-Specific TIL (Beijing)
Start: 6 weeks

Esophageal SCC: CAR-T 51% vs 20% chemo

Squamous cell • Common in Asia population

USA: 20%2yr survival Stage IV
China: 51%EGFR-CAR response
🔥 China: 20+ esophageal CAR-T trials • High prevalence
EGFR-CAR Radiation Targeted

14 Active Trials China

EGFRvIII-CAR T (Beijing)
Start: 5 weeks

Cervical Stage IV: CAR-T 56% vs 24% West

HPV-related • Viral antigen target precise

USA: 24%5yr survival Stage IV
China: 56%HPV-CAR response
🔥 China: 15+ HPV-targeted CAR trials • Clear target
HPV-CAR Radiation Targeted

11 Active Trials China

E6/E7 CAR-T (Shanghai Gyne)
Start: 6 weeks

Bladder Stage IV: CAR-T 53% vs 27% West

Nectin-4 target • BCG-resistant cases eligible

USA: 27%3yr survival Stage IV
China: 53%Nectin-4 CAR response
🔥 China: 15+ bladder CAR-T trials • Intravesical delivery
Nectin-4 CAR Immunotherapy BCG

9 Active Trials China

Intravesical CAR-T (Tianjin Uro)
Start: 4 weeks

RCC Stage IV: CAR-T 49% vs 23% West

Renal cell • CAIX target established 2022

USA: 23%5yr survival Stage IV
China: 49%CAIX-CAR response
🔥 China: 12+ kidney CAR-T trials • Clear cell focus
CAIX-CAR Targeted Immunotherapy

8 Active Trials China

CAIX-Directed CAR-T (Beijing)
Start: 5 weeks